Skip to main content
. 2018 May 3;45(10):1781–1794. doi: 10.1007/s00259-018-4029-9

Fig. 5.

Fig. 5

68Ga-PSMA-HBED-CC-IRdye800CW, a novel dual labelled PSMA inhibitor with promising properties that may allow PET/CT to be combined with fluorescence-guided surgery for the evaluation of prostate cancer [12]